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burse different essential medicine causing inequity to access essential medicines. 
Federal ministry of health tried to unify essential list in 10 different cantons by 
Order from 2011 but this has never been fully implemented by all 10 cantonal HIFs. 
In Republic of Srpska (RS) there is one HIF, and 3rd administrative part Brcko District 
(BD) has its own HIF. Methods: We compered average reimbursed prices from 
main HIFs in B&H for most commonly proscribed primary care medicines based 
on 2014 Annual report on medicines utilization issued by Agency for medicines of 
B&H. Average prices have been taken into account since different presentation of 
the same INN (dosage and number of units in pack) are reimbursed. All prices are 
expressed in EUR and represents prices paid by HIF. Results: Comparing Federal 
MoH proposed reimbursed prices and prices from RS HIF s it is noted that prices are 
higher in RS (+20% on average) except in case of bisoprolol. The highest difference is 
for atorvastatin (+39%). Prices in BD are on average lover for -14% vs Federal prices 
and -43% vs RSHIF prices. There are high differences among cantonal RB prices 
comparing to Federal proposal and among main 3 cantons. Atorvastatin is not reim-
bursed in Tuzla and Zenica Canton, while rosuvastatin is not reimbursed in Tuzla 
Canton and BD. Also different copayment levels are introduced at cantonal HIF level 
causing additional inequalities. ConClusions: Different prices cause inequity to 
access essential medicines for inhabitants living in different administrative regions. 
It also impact market indifferences. Implementation of unified and centralized 
pricing system would positively impact on access to medicines and HIFs spending.
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objeCtives: Generally, socioeconomic conditions can be recognised as core determi-
nants of health status. The aim of this study is to identify how the sociodemographic 
characteristics of the population influence self-rated health (SRH) as well as to exam-
ine the relationship between SRH and subjective social status (SSS). Methods: A 
cross-sectional survey was conducted on a representative national sample of 2012 
adult individuals. Respondents were asked to self-evaluate their social status on a 
10-step ladder-based survey tool where 10 represented the highest subjective social 
stratum. Data were analyzed through an ordinal logistic regression model to identify 
the unique characteristics that exist between SRH, sociodemographic characteristics 
and SSS. Results: Older individuals and chronic patients had a lower probability of 
rating their health high. Odds ratio for older age was 0.74 and for the non existence 
of a chronic disease was 4.30. A relation between social interactions and health levels 
was documented. This can be interpreted by the positive relation (OR= 1.27) between 
SRH and social support, where individuals who reported having more people to rely 
on had a higher probability to self-rate their health higher. In terms of the SSS, there 
is a significant statistical positive association (OR= 1.24) with SRH. It is worth adding 
that the highest percentage of respondents (27.4%) rated their SSS as moderate (step 
5), while 69.5% of the respondents reported a positive health level. ConClusions: 
This study provides evidence on the association between socioeconomic factors and 
SRH among the Greek adult population. This contributes to the understanding of the 
complex inter-relationships leading to health inequalities in societies with prevalent 
socioeconomic disparities. Since Greece is going through a deep economic recession, 
such rising inequalities are observed.
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objeCtives: Evidence based medicine has been used for about two decades as meth-
odology for obtaining, evaluating and presenting information on health related topics. 
The present study investigated the question of the appearance of the ideas of evi-
dence based medicine in documents describing the functioning of health care sys-
tems in countries not belonging to the European Union. Methods: The documents 
available in the European Observatory on Health Systems and Policies database were 
considered to reliable represent the health system of non-European Union countries 
too. Electronic search was carried out, each ‘evidence’ expression was categorised 
afterwards into different topics. Deadline of the search was March, 2015. Results: 
The cumulative length of the documents was 4680 pages; there was no document 
without mentioning the idea of evidence based medicine. Among the altogether 431 
mentionings of evidence based medicine, we were able to categorise 295 representa-
tions of the idea into one of the following 4 topics: 1. resources of health care, 2. health 
technology assessment, 3. organisation of health care and 4. environment of health 
care within the society. Evidence based medicine was mentioned 49 times in connec-
tion with the resources of health care, whereas 20 mentionings were related to health 
technology assessment. Organisation of health care was mentioned together with evi-
dence based medicine at 152 occasions, whereas the idea of evidence based medicine 
was related to the social environment of health care in 74 instances. ConClusions: 
The results of the present data collection indicate that the methodology of evidence 
based medicine has already been widely used within the documents describing health 
systems and policies also in countries not belonging to the European Union.
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objeCtives: There was a significant regulation of the inpatient care hospital 
capacity in the last decade in Hungary. The ratio of short- and long term care hos-
population has lost its job and in many cases the insurance capacity.The objective 
of this study was to identify the problems related with the access to health care 
services of Greek and immigrants who visitednon-governmental clinics in Athens, 
in order to receive free of charge health services. The inclusion criteria for participa-
tion in the study was the satisfactory level of understanding the Greek language, 
the lack of insurance or employment or alternatively being under the risk of pov-
erty. Methods: A cross-sectional study was conducted. The study population con-
sisted of 100 people, Greek and migrants, living in Athens. The participants were> 18 
years. The research team developed a questionnaire that included information about 
sociodemographic characteristics, health status, public healthservices knowledge 
and utilization and difficulties in health services access. The questionnaire was 
completed through interviews. Data analysis was performed with the IBM SPSS 
19.0 (Statistical Package for Social Sciences). Results: The lack of knowledge about 
programs which may provide access to health care services was among the most 
significant findings. More than 90% of the respondents reported that they were not 
informed about the legal arrangements voted recently for the universal coverage of 
uninsured population. Other significant barriers in accessing health care services 
included cost as 92, 1% of the respondents stated that they couldn’t afford to buy 
the recommended treatment and the bureaucratic procedures. ConClusions: 
The last law amendments ensuring accessibility of vulnerable groups to health 
services are definitely towards the right direction. Yet, it is important that equal 
access should be re-established along with the provision of integrated, qualitative 
and undifferentiated care.
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objeCtives: Economic evaluation is well regarded by policymakers as a tool 
for healthcare priority setting, but is often not used in practice. We explored the 
perspectives of both users (stakeholders) and producers (health economists) of 
economic evaluations to understand the underutilisation of economic evidence 
in healthcare decision making. Methods: A mixed methods approach was 
used. Stakeholders (health professionals, healthcare administrators or managers, 
and health researchers) were surveyed regarding to understand the factors that 
determine whether they use evidence from economic evaluations. The relative 
importance of these factors was measured using a discrete choice experiment. 
Perspectives of health economists were gathered through semi-structured inter-
views. Results: The survey was answered by 93 stakeholders. Important factors 
to stakeholders included quality of clinical evidence, quality of economic evidence, 
timeliness, applicability, communication and conflicts of interest. Ten health econo-
mists participated in semi-structured interviews. They discussed methods they 
used to translate their research into healthcare practice. Topics discussed included 
the nature of stakholder engagement and how the production of of economic evi-
dence was tailored to meet specific contextual needs. It was generally considered 
best when stakeholder engagement begins early and is maintained throughout the 
research process. ConClusions: These findings are being used to inform recom-
mendations for translating evidence from economic evaluation into clinical practice. 
Such recommendations need to balance stakeholder needs with the constraints 
that health economists face.
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objeCtives: In order to launch a reimbursed drug in France, products with mar-
keting authorization (MA) are firstly assessed by the Transparency Committee (CT, 
Commission de la Transparence) and then undergo pricing negotiations with the 
Pricing Committee (CEPS, Comité Economique des Produits de Santé). This process 
has an impact on time to market launch (ML). The Temporary Authorization for 
Use (ATU) allows early access of drugs to patients before MA and could reduce 
time to ML. Our aim was to compare the time from MA to ML between ATU and 
non-ATU drugs. Methods: Using the Prismaccess database, research was carried 
out to identify ATU and non-ATU drugs to calculate their time to ML from January 
2013 to June 2015. Mean total time (MA-ML) and mean intermediate times (MA-CT 
opinion and CT opinion-ML) were compared between groups using Mann-Whitney 
test (α = 0.05). Results: French health authorities assessed 7 ATU and 18 non-ATU 
drugs during the reviewed period. The mean total time (MA-ML) was shorter for ATU 
drugs compared to non-ATU drugs (281±58 versus 493±245 days; p= 0.017). Similarly, 
the mean time from MA to CT opinion was shorter for ATU drugs compared to 
non-ATU drugs (141 ± 39 versus 489 ± 727 days; p= 0.004). In contrast, no difference 
was reported in time from CT opinion to ML (143 ± 43 versus 166 ± 101 days; p > 
0.05). ConClusions: Overall, ATU drugs seem to launch faster with respect to the 
total time from MA to ML which is mainly due to the reduced time from MA to CT 
opinion. Indeed, the specific regulatory framework for ATU drugs requires pharma-
ceutical companies to submit a CT dossier within one month of MA. Nevertheless, 
the pricing negotiation process, i.e. time from CT opinion to ML, does not change 
between ATU and non-ATU drugs.
PHP75
diffeRences in ReimBuRsemenT PRices and inequaliTies To access 
mosT commonly PRescRiBed medicines in Bosnia and HeRzeGovina
Catic T
ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
objeCtives: Bosnia and Herzegovina have highly decentralized healthcare system 
which is financed by 12 different health insurance funds (HIF) based on administra-
tive organization of the country. Depending on budget ability different HIFs reim-
